BRKR - CIK 0001109354
BRUKER CORP trades as BRKR and has a market capitalization of $8.36 B, making it the #1042 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.44B, up 2.1% from the prior year and net income of -$8.30M. This page tracks BRUKER CORP through 1,361 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years BRUKER CORP's revenue grew from $1.61B to $3.44B, a compound annual growth rate of 8.8%. Net profit margin compressed from 9.5% to -0.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-06 |
**Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically**
To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins.
MUNICH--(BUSINESS WIRE)-- At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division ( Bruker Corporation, Nasdaq: BRKR) announces the European launch of **MyGenius PRO®**, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput **BeGenius®** system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - enhancing laboratory efficiency and supporting higher-throughput volume testing needs.
The largest companies sharing BRUKER CORP's SEC industry classification (laboratory analytical instruments).
BRUKER CORP (BRKR) has a market capitalization of $8.36 B as of 2026-06-10, ranking #1042 among US-listed companies.
BRUKER CORP reported revenue of $3.44B for fiscal year 2025, an increase of 2.1% year over year.
In its latest fiscal year BRUKER CORP reported a net loss of $8.30M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
**_MALDI Biotyper (MBT): Launch of proprietary MBT Easy T Kit for consistent sample transfer to MALDI target plates_**
**_Bruker Spatial Biology features new GeoMx-to-CellScape and CellScape-to-CosMx cross-platform workflows and first-of-its-kind 208-plex CellScape XR spatial proteomics datasets_**